Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 15:59:56 28/05/2024 BST After market 16:20:00
915.7 DKK -0.43% Intraday chart for Novo Nordisk A/S 917.5 +0.20%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Novo Nordisk Tells US Senate Health Committee Chair Sanders It Only Keeps 60% of Ozempic, Wegovy List Price MT
Novo Nordisk's Boost to Danish Employment Levels More than Expected, Economic Councils Says MT
Novo Nordisk Said to Defend Drug Prices Amid Heat from US Lawmakers MT
Weight-loss drug forecasts jump to $150 billion as supply grows RE
NOVO NORDISK : Deutsche Bank reaffirms its Buy rating ZD
Novo Nordisk: share buybacks continue CF
Wegovy users have less kidney-related health problems, analysis of Novo study finds RE
Health Care Down on Rotation Out of Sector - Health Care Roundup DJ
News Highlights : Top Company News of the Day - Friday at 5 PM ET DJ
US FDA panel votes against use of Novo Nordisk's weekly insulin in type 1 diabetes patients RE
News Highlights : Top Company News of the Day - Friday at 3 PM ET DJ
Top Midday: Intuit, Workday Shares Tumble on Lowered Guidance; Ozempic Reduces Kidney Disease Events, Deaths From Cardiovascular Causes; NHTSA Finds 9 Additional Incidents Tied to Waymo MT
European Equities Mostly Down Friday; German Economy Begins 2024 With 'Positive Sign' MT
NOVO NORDISK : JP Morgan reiterates its Buy rating ZD
Novo Nordisk's Ozempic Reduces Kidney Disease, Death Risk According to Study of Patients With Type 2 Diabetes MT
Ozempic Slows Kidney Disease, Novo Nordisk Study Finds DJ
FMC, Fresenius and Davita rise after Ozempic news DP
Germany's Gerresheimer to acquire Blitz LuxCo for $866 mln RE
Novo Nordisk's Weekly Insulin Flagged for Low Blood Sugar Risk MT
Novo Nordisk Once-Weekly Insulin Icodec Poses Hypoglycemia Risk, FDA Says MT
Novo Nordisk Confirms Fire at Office Building in Denmark; No Injuries Reported MT
US FDA staff flags risk of low blood sugar for Novo Nordisk's weekly insulin RE
Novo Nordisk Faces Second Fire at Danish Headquarters Within a Week MT
Fire Breaks Out in Novo Nordisk Denmark Office Building MT
European shares to hit pause before rising again in 2025 RE
Chart Novo Nordisk A/S
More charts
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
919.7 DKK
Average target price
909.2 DKK
Spread / Average Target
-1.14%
Consensus
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. News Novo Nordisk A/S
  5. Novo Nordisk Plans First Bond Sale in 2 Years